Follitropin delta – experience from clinical practice

Česká verze

Authors: K. Frühaufová
Authors place of work: Gynem IVF a. s. Praha
Published in the journal: Ceska Gynekol 2023; 88(4): 310-312
Category: Lékový profil
doi: https://doi.org/10.48095/cccg2023310

Summary

New recombinant gonadotropin-follitropin delta produced on human cell lines PER.C6 shows the same glycosylation profiles as human follicle stimulating hormone in comparison with recombinant gonadotropins produced on animal cell lines. The aim of the article is to summarize published data.

Keywords:

assisted reproduction – infertility – ovarian hyperstimulation syndrome – anti-Müllerian hormone

Zdroje

1. Lunenfeld B, Bilger W, Longobardi S et al. The development of gonadotropins for clinical use in the treatment of infertility. Front Endocrinol (Lausanne) 2019; 10 : 429. doi: 0.33 89/ fendo.2019.00429.

2. Bagócsi T, Rumpík D, Křenek O et al. Nový nástroj pro personalizaci ovariální stimulace: výsledky studie CERES při použití nového gonadotropinu –⁠ folitropinu delta. Ceska Gynekol 2021; 86 (2): 86–92. doi: 10.48095/cccg202 186.

3. Bousfield GR, Dias JA. Synthetis and secretion of gonadotropins including structure-function correlates. Rev Endocr Metab Disord 2011; 12 (4): 289–302. doi: 10.1007/s11154-011-91 91-3.

4. Shao F, Jiang Y, Ding S et al. Pharmacokinetics and safety of follitropin delta in gonadotropin down-regulated healthy chinese women. Clin Drug Investig 2023; 43 (1): 37–44. doi: 10.1007/s40261-022-01232-9.

5. Steward RG, Lan L, Shah AA et al. Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles. Fertil Steril 2014; 101 (4): 967–73. doi: 10.1016/j.fertnstert.2013.12.026.

6. Fleming R, Seifer DB, Frattarelli JL et al. Assessing ovaria: antral follicle count versus anti-Müllerain hormone. Reprod Biomed Online 2015; 31 (4): 486–96. doi: 10.1016/j.rbmo.2015.06.015.

7. Moolhuijsen LM, Visser JA. Anti-Müllerian hormone and ovarian reserve: update on assessing ovarian functions. J Clin Endocrinol Metab 2020; 105 (11): 3361–3373. doi: 10.1210/ clinem/dgaa513.

8. Aboulghar M. Symposium: update on prediction and management of OHSS. Prevention of OHSS. Reprod Biomed Online 2009; 19 (1): 33–42. doi: 10.1016/s1472-6483 (10) 60043-0.

9. Corbett S, Shmorgun D, Claman P. The prevention of ovaria hyperstimulation syndrome. J Obstet Gynaecol Can 2014; 36 (11): 1024–1033. doi: 10.1016/S1701-2163 (15) 30417-5.

10. Blockeel C, Griesinger G, Rago R et al. Prospective multicenter non-interventional real-world study to assess the patterns of use, effectiveness and safety of follitropin delta in routine clinical practice (the PROFILE study). Front Endocrinol (Lausanne) 2022; 13 : 992677. doi: 10.3389/fendo.2022.992677.

11. Nyboe Andersen A, Nelson SM, Fauser BC et al. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril 2017; 107 (2): 387.e4–396.e4. doi: 10.1016/ j.fertnstert.2016.10.033.

12. Bosch E, Havelock J, Martin FS et al. Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial. Reprod Biomed Online 2019; 38 (2): 195–205. doi: 10.1016/j.rbmo.2018.10.012.

13. Qiao J, Zhang Y, Liang X et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Hum Reprod 2021; 36 (9): 2452–2462. doi: 10.1093/humrep/deab155.

14. Ishihara O, Arce JC. Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ ICSI patients: a randomized controlled trial. Reprod Biomed Online 2021; 42 (5) : 909–918. doi: 10.1016/ j.rbmo.2021.01.023.